For help on how to get the results you want, see our search tips.
2 results
Categories
Human Remove Human filter
Medicine
Referrals Remove Referrals filter
Referral status
European Commission final decision Remove European Commission final decision filter
Recommendation provided by Pharmacovigilance Risk Assessment Committee Remove Recommendation provided by Pharmacovigilance Risk Assessment Committee filter
Referral PRAC recommendation
Suspension Remove Suspension filter
Risk minimisation measures Remove Risk minimisation measures filter
Referral type
Article 31 referrals Remove Article 31 referrals filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral authorisation model
Centrally and nationally authorised products (mixed) Remove Centrally and nationally authorised products (mixed) filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Quinolone- and fluoroquinolone-containing medicinal products
nalidixic acid, pipemidic acid, cinoxacin, enoxacin, pefloxacin, lomefloxacin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, prulifloxacin, rufloxacin, flumequin, associated names: Quinsair, Article 31 referrals
Status: European Commission final decision, opinion/position date: 15/11/2018, EC decision date: 11/03/2019, Last updated: 08/06/2023 -
List item
Referral: Methotrexate containing medicinal products
methotrexate, associated names: Nordimet, Jylamvo, Ledertrexate, Maxtrex, Metex, Metoject, Article 31 referrals
Status: European Commission final decision, opinion/position date: 22/08/2019, EC decision date: 21/10/2019, Last updated: 31/10/2019